US n = 31 | KDD n = 31 | Control n = 20 | Between group p values | |
---|---|---|---|---|
Physical functioning | ||||
Before treatment | 45.74 ± 21.26b | 47.09 ± 20.72b | 59.00 ± 27.65b | 0.104* |
1st month after treatment | 61.51 ± 24.06b | 66.77 ± 20.02b | 73.00 ± 17.72b | 0.172* |
3rd month after treatment | 61.61 ± 26.43b | 70.48 ± 19.20b | 75.00 ± 17.91b | 0.087* |
Within group p | 0.003** | < 0.001** | 0.036** | |
Role -physical | ||||
Before treatment | 0 (0–100)c,d | 0 (0–100)c,d | 87.5 (0–100)c | 0.002*** |
1st month after treatment | 75 (0–100)d | 100 (0–100)d | 100 (0–100) | 0.114*** |
3rd month after treatment | 75 (0–100)d | 100 (0–100)d | 100 (0–100) | 0.063*** |
Within group p | < 0.001**** | < 0.001**** | 0.063**** | |
Role -emotional | ||||
Before treatment | 34.38 ± 39.93a,b | 47.29 ± 47.75b | 68.30 ± 39.75a | 0.027* |
1st month after treatment | 64.54 ± 41.24b | 76.32 ± 39.65b | 80.00 ± 41.03 | 0.347* |
3rd month after treatment | 63.35 ± 41.70b | 81.67 ± 35.37b | 85.00 ± 36.63 | 0.081* |
Within group p | 0.001** | 0.006** | 0.110** | |
Vitality | ||||
Before treatment | 45.48 ± 14.16b | 48.38 ± 18.63b | 49.50 ± 17.31 | 0.576* |
1st month after treatment | 54.83 ± 15.62b | 56.45 ± 21.45b | 49.75 ± 16.50 | 0.234* |
3rd month after treatment | 55.80 ± 19.58b | 56.29 ± 23.55b | 49.00 ± 18.32 | 0.075* |
Within group p | 0.005* | 0.019* | 0.957* | |
Emotional well-being | ||||
Before treatment | 56.25 ± 15.69b | 58.70 ± 16.21b | 61.10 ± 12.40 | 0.382* |
1st month after treatment | 63.48 ± 13.13b | 65.03 ± 16.68 | 61.30 ± 15.30 | 0.367* |
3rd month after treatment | 62.00 ± 19.34 | 67.61 ± 17.83b | 61.15 ± 15.13 | 0.671* |
Within group p | 0.029* | 0.021* | 0.996* | |
Social functioning | ||||
Before treatment | 50 (25–88)d | 50 (25–100)d | 63 (10–100)d | 0.272*** |
1st month after treatment | 63 (37.5–100)d | 87.5 (0–100)d | 87.5 (13–100)d | 0.221*** |
3rd month after treatment | 63 (13–100)c,d | 100 (37.5–100)c,d | 88 (50–100)d | 0.012*** |
Within group p | 0.001**** | < 0.001**** | < 0.001**** | |
Pain | ||||
Before treatment | 38 (0–68)c,d | 45 (0–80)d | 45 (23–70)c,d | 0.007*** |
1st month after treatment | 48 (10–100)d | 67.5 (35–100)d | 67.5 (20–90)d | 0.233*** |
3rd month after treatment | 58 (10–100)d | 70 (22.5–100)d | 63.7 (22.5–90)d | 0.753*** |
Within group p | < 0.001**** | < 0.001**** | 0.021**** | |
General health | ||||
Before treatment | 50 (25–80) | 60 (20–85)d | 57.5 (25–100) | 0.132*** |
1st month after treatment | 55 (30–80) | 65 (15–95) | 57.5 (30–100) | 0.330*** |
3rd month after treatment | 55 (25–95) | 65 (30–95)d | 62.5 (30–100) | 0.215*** |
Within group p | 0.248**** | 0.030**** | 0.590**** | |
Mental Health | ||||
Before treatment | 38.70 ± 18.07b | 34.51 ± 15.24b | 42.25 ± 18.60 | 0.285* |
1st month after treatment | 60.48 ± 26.43b | 59.67 ± 23.87b | 52.50 ± 26.77 | 0.514* |
3rd month after treatment | 56.61 ± 30.77b | 56.41 ± 25.77b | 57.50 ± 27.02 | 0.990* |
Within group p | < 0.001** | < 0.001** | 0.099** |